Molecular heterogeneity of second and fourth components of complement and their genes in systemic sclerosis and association of HLA alleles A1, B8 and DR3 with limited and DR5 with diffuse systemic sclerosis.
Deficiency of the complement component C4 at the functional, protein and gene level and deficiency of complement component C2 at the functional level were investigated and HLA analysis was performed on patients with limited and diffuse systemic sclerosis (SSc). One of the patients with limited SSc (n = 15) had subnormal C4, 1 subnormal C2 and 1 subnormal C4 and C2 activities; the latter patient had HLA alleles A11;B35;Dw1 associated with type II C2 deficiency and therefore most likely had a defect at the C2 locus. One of the patients with diffuse SSC (n = 12) had subnormal C4 and 1 subnormal C4 and C2 activities. C2 deficiencies in patients other than the one with the haplotype associated with C2 deficiency appeared not to be determined by the gene at the C2 locus. The incidence of partial C2 deficiency in a normal Caucasian population is reported to be 16 in 10,000, and that of partial C4 deficiency also appears to be very low. The percentages of C4A*Q0 and C4B*Q0 alleles in normal controls (n = 45) were within the reported range. Seven patients with limited SSc (n = 14) had one or two C4A*Q0 alleles and 2 with diffuse SSc (n = 13) had one C4A*Q0 allele. Thus, the incidence of C4A*Q0 was higher than normal in limited SSc and within the normal range in diffuse SSc. The two-sided Fisher's exact test applied on these data revealed that the association of C4A*Q0 with limited SSc did not reach a significant level (p = 0.10). Two of the 3 patients with limited SSc, who had two C4A*Q0 alleles, carried a heterozygous C4A-21-hydroxylase A (OHA) gene segment deletion as detected by Southern blotting. There was no correlation between the subnormal activity of C4 and the occurrence of one or two C4A*Q0 (and C4A-21-OHA segment deletion). HLA alleles A1, B8 and DR3 (p = 0.002) were associated with limited SSc (n = 23) and DR5(w11) (p = 0.018) with diffuse SSc (n = 17).
Venneker
G T
GT
Department of Dermatology, University of Amsterdam, Academisch Medisch Centrum, Amsterdam, The Netherlands.
van den Hoogen
F H
FH
van Meegen
M
M
de Kok-Nazaruk
M
M
Hulsmans
R F
RF
Boerbooms
A M
AM
de Waal
L P
LP
Bos
J D
JD
Asghar
S S
SS
D000483:Alleles; D016022:Case-Control Studies; D003175:Complement C2 / Q000172:deficiency / Q000235:genetics*; D003181:Complement C4 / Q000172:deficiency / Q000235:genetics*; D006680:HLA Antigens / Q000235:genetics*; D015788:HLA-A1 Antigen / Q000235:genetics; D015795:HLA-B8 Antigen / Q000235:genetics; D015803:HLA-DR3 Antigen / Q000235:genetics; D015805:HLA-DR5 Antigen / Q000235:genetics; D006239:Haplotypes; D006801:Humans; D012595:Scleroderma, Systemic / Q000201:enzymology / Q000235:genetics* / Q000276:immunology*; D013255:Steroid 21-Hydroxylase / Q000235:genetics
D003175:Complement C2; D003181:Complement C4; D006680:HLA Antigens; D015788:HLA-A1 Antigen; D015795:HLA-B8 Antigen; D015803:HLA-DR3 Antigen; D015805:HLA-DR5 Antigen; D013255:Steroid 21-Hydroxylase